Expected Findings of the SWOG S1505 Trial in Pancreatic Cancer

Davendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the SWOG S1505 trial, which is exploring perioperative mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.